Enanta Pharmaceuticals, Inc. (ENTA)
Enanta Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Watertown, MA, US. The stock last traded at $13.43, down 0.67% on the session, giving a market capitalisation of $390.5M. On trailing twelve-month figures it carries a trailing P/E of -5.27, a net margin of -96.9%. Its beta of 0.93 implies it has historically moved less than the broad market.
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Enanta Pharmaceuticals, Inc. is most often compared with the following Healthcare names: